ABOS - Acumen Pharmaceuticals, Inc. Book Valuation of Business

Public company logo of Acumen Pharmaceuticals, Inc. (ABOS)

Acumen Pharmaceuticals (ABOS) is developing treatments for Alzheimer's disease, leveraging a strategic R&D alliance with a pharma behemoth to fund clinical trials. This chart of the company's market valuation on GURU.Markets, where the indicator stands at 0.03, links stringent FDA requirements and patent protection to a full production outsourcing model. Such an approach allows the scientific team to avoid capital expenditures while maintaining flexibility under strict regulatory conditions.

ABOS Acumen Pharmaceuticals, Inc. Book Capitalization (07/04/2022 - 10/27/2026)

Metric breakdowns and analytics for Acumen Pharmaceuticals, Inc. (ABOS)

- price and consensus price forecast:
Market Price Acumen Pharmaceuticals, Inc|ABOS - Price Target Chart
- market capitalization data:
Market Capitalization Acumen Pharmaceuticals Inc.|ABOS - Total Company Value
- book capitalization data:
Equity per Share Acumen Pharmaceuticals|ABOS - Book Capitalization|Market-to-Book Ratio acumenpharm.com|ABOS - Cumulative Company Assets
- debt and liquidity data:
Total Debt to Capital Acumen Pharmaceuticals|ABOS - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Acumen Pharmaceuticals Inc.|ABOS - Company Debts|Debts to Book Value Acumen Pharmaceuticals Inc.
Summary company analysis:ABOS - Acumen Pharmaceuticals, Inc
Flagship merchandise of Acumen Pharmaceuticals Inc.

Book value capitalization measures the residual value of net assets minus all liabilities, allowing an investor to assess the real intrinsic value of the business between quarterly reports. An analysis of the book capital of Acumen Pharmaceuticals (ABOS) reveals the issuer's degree of financial stability in the face of high development costs for Alzheimer's disease therapy and the risks of clinical trial failure.

Competitor analysis for Acumen Pharmaceuticals

BIIB: Total Stockholders' Equity|Neurocrine Biosciences - Company Book Value|RGC (regencellbioscience.com) - Book Valuation of Business|Company Book Value Axsome Therapeutics, Inc. (AXSM)|Accounting Capitalization ACADIA Pharma|Xenon Pharmaceuticals Inc - Book Capitalization|Total Stockholders' Equity Viking Therapeutics Corp VKTX|Company Net Assets SUPN (Supernus Pharmaceuticals)|catalystpharma.com - Book Capitalization|Company Book Value Denali Therapeutics Inc. (DNLI)|HRMY: Accounting Value of Company|Company Book Value BHVN|Amylyx Corp (AMLX) - Total Stockholders' Equity|TRVI (Trevi Therapeutics) - Book Capitalization|Book Capitalization praxismedicines.com|Book Capitalization AVXL (Anavex Life Sciences Corp.)|Company Net Assets CeriBell Inc CBLL|Company Net Assets PRTA (prothena.com)|Alector Inc. - Book Capitalization|ANNX: Company Book Value|OMER - Company Net Assets|Book Capitalization NGNE|ACIU (AC Immune S.A.) - Total Stockholders' Equity|Company Book Value Voyager Pharma (VYGR)|Accounting Capitalization Neumora Corp (NMRA)|Scilex Holding Company (SCLX) - Company Net Assets|Accounting Value of Company TVGN (tevogen.com)|Alpha Cognition Inc. (ACOG) - Company Book Value|Net Asset Value cogrx.com CGTX|Book Capitalization Inhibikase (IKT)|SAVA - Accounting Value of Company|ASRT: Book Capitalization|COYA (Coya Therapeutics) - Book Capitalization|VTGN - Company Book Value|Accounting Value of Company OVID|Company Book Value CRVO (CervoMed Inc)|Company Net Assets alteritytherapeutics.com (ATHE)|Book Capitalization CLNN (Clene)|Book Capitalization PepGen Inc PEPG|JUNS: Book Capitalization|RLMD - Company Net Assets|Book Capitalization ANVS|Total Stockholders' Equity Grace Therapeutics|AIFF (Firefly Neuroscience, Inc) - Company Net Assets|Book Capitalization ANEW Medical, Inc. (KLTO)|Company Net Assets NeuroSense Therapeutics|Total Net Assets Reviva Pharmaceuticals Holdings Inc. (RVPH)|Book Capitalization MTVA|Book Valuation of Business NeurAxis Inc NRXS|HSDT: Book Capitalization|PASG - Company Net Assets|NEUP: Book Capitalization|NERV (Minerva Neurosciences Inc) - Book Capitalization|Company Book Value Athira|Company Book Value ADXN|ALZN (Alzamend Neuro, Inc.) - Company Book Value|Book Valuation of Business cyclerion.com (CYCN)|Book Capitalization PTIX (Protagenic Therapeutics, Inc.)|Book Capitalization Pasithea Therapeutics Corp KTTA|CRGT - Book Capitalization|ATXI: Company Book Value|Company Book Value BCLI|CARA (caratherapeutics.com) - Total Stockholders' Equity|CHRO: Company Book Value|Book Valuation of Business ELYM|Company Book Value Intra-Cellular Therapies ITCI|Accounting Capitalization Longboard (LBPH)|MRNS: Book Capitalization|NKGN - Total Stockholders' Equity|NeuroBo Pharmaceuticals, Inc. - Company Net Assets|SAGE: Book Capitalization|Company Book Value Neurotrope SNPX|TRVN (Trevena Inc) - Accounting Value of Company|Company Book Value VIGL (Vigil Neuroscience Inc.)|Total Stockholders' Equity Anew Medical Inc.|Book Capitalization CERE